High materiality7/10
Neurocrine price target raised to $200 from $175 at Wells Fargo
Why it may matterVerify against the original reporting
Upside potential; bullish setup.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
NBIX target increased to $200; current price $171.55; upside evident.
- Target: $200; Current: $171.55; Firm: Wells Fargo
Key facts
- 01
Target: $200
- 02
Posted price: $171.55
- 03
Analyst firm: Wells Fargo
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.